1
Sergei M Gryaznov, Ronald G Schultz, Jer kang Chen: Oligonucleotide N3.fwdarw.P5 phosphoramidates. Lynx Therapeutics, Stephen C Macevicz, John D Mendlein, Vincent M Powers, October 12, 1999: US05965720 (189 worldwide citation)

Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form m ...


2
Sergei M Gryaznov, Ronald G Schultz, Jer kang Chen: Oligonucleotide N3.fwdarw.P5 phosphoramidates: triplex DNA formation. Lynx Therapeutics, January 7, 1997: US05591607 (136 worldwide citation)

Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form m ...


3
Sergei M Gryaznov, Ronald G Schultz, Jer Kang Chen: Oligodeoxyribonucleotide N3 P5 phosphoramidates. Lynx Therapeutics, Stephen C Macevicz, March 10, 1998: US05726297 (135 worldwide citation)

Modified oligodeoxyribonucleotide 3'--NHP (O) (O.sup.-) O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these comp ...


4
Sergei M Gryaznov, Ronald G Schultz, Jer kang Chen: Oligonucleotide N3-P5 phosphoramidates: hybridization and nuclease resistance properties. Lynx Therapeutics, Gary R Fabian, John D Mendlein, November 17, 1998: US05837835 (132 worldwide citation)

Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form m ...


5
Sergei M Gryaznov, Ronald G Schultz, Jer kang Chen: Oligonucleotide N3-P5 phosphoramidates: hybridization and nuclease resistance properties. Lynx Therapeutics, February 4, 1997: US05599922 (129 worldwide citation)

Modified oligonucleotide 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form mo ...


6
Sergei M Gryaznov, Ronald G Schultz, Jer Kang Chen: Oligonucleotide N3.fwdarw.P5 phosphoramidates: hybridization and nuclease resistance properties. Lynx Therapeutics, May 20, 1997: US05631135 (128 worldwide citation)

Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form m ...


7

8
Sergei Gryaznov, Ronald G Schultz: Oligo-2-fluoronucleotide N3->P5 phosphoramidates. Lynx Therapeutics, Stephen C Macevicz, Vincent M Powers, November 4, 1997: US05684143 (41 worldwide citation)

A new class of oligonucleotide N3'.fwdarw.P5' phosphoramidates having 2' fluoro substituents are provided that have superior acid stability. The invention includes oligo-2'-fluoronucleotide N3'.fwdarw.P5' phosphoramidates, methods of synthesis, and duplexes and triplexes formed with DNA and RNA. Com ...


9
Marvin Stark, Ronald G Schultz, Robert A Spychalski: Railway hopper car closure actuating mechanism. Pullman Incorporated, Richard J Myers, Stephen D Geimer, September 30, 1980: US04224877 (23 worldwide citation)

An apparatus for pivoting and locking a door on the bottom of a rail hopper car includes a locking mechanism for locking the door when closed and a lever mechanism for pivoting the door between closed and open positions. The locking mechanism and lever mechanism are separate but are operated by a si ...


10
Bernard L Hirschbein, Karen L Fearon, Sergei M Gryaznov, Sarah N McCurdy, Jeffery S Nelson, Ronald G Schultz: Solid phase synthesis of oligonucleotide N3-P5 phosphoramidates. Lynx Therapeutics, Stephen C Macevicz, Vincent M Dehlinger & Associates Powers, October 20, 1998: US05824793 (18 worldwide citation)

The invention provides a method of synthesizing oligonucleotide N3'.fwdarw.P5' phosphoramidates using an amine-exchange reaction of phosphoramidites in which a deprotected 3'-amino group of a solid phase supported oligonucleotide chain is exhanged for the amino portion of a 5'-phosphoramidite of an ...